Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (121-130 of 254) with videos related to

Pageof 26
Sort By:
AIDS (London, England)|April 19, 2015
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccinationAs'ad E Bhorat, Shabir A Madhi, France Laudat, et al.
The Journal of Infectious Diseases|April 5, 2012
Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidisAnnaliesa S Anderson, Ingrid L Scully, Yekaterina Timofeyeva, et al.
Obstetrics and Gynecology|January 6, 2006
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trialConstance Mao, Laura A Koutsky, Kevin A Ault, et al.
Mayo Clinic Proceedings|May 13, 2005
Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trialGregory A Poland, Robert M Jacobson, Laura A Koutsky, et al.
Journal of the Pediatric Infectious Diseases Society|January 25, 2016
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy AdolescentsTimo Vesikari, Jacek Wysocki, Johannes Beeslaar, et al.
Vaccine|August 31, 2015
Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infectionIngrid L Scully, Yekaterina Timofeyeva, David Keeney, et al.
Vaccine|May 22, 2013
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and olderLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Acta Obstetricia Et Gynecologica Scandinavica|October 19, 2007
Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristicsFinn Egil Skjeldestad, Vinay Mehta, Heather L Sings, et al.
Vaccine|August 7, 2004
A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineKevin A Ault, Anna R Giuliano, Robert P Edwards, et al.
The Pediatric Infectious Disease Journal|October 19, 2013
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Shelly Senders, et al.
Pageof 26

Showing results (121-130 of 254) with videos related to

Sort By:
Pageof 26
AIDS (London, England)|April 19, 2015
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccinationAs'ad E Bhorat, Shabir A Madhi, France Laudat, et al.
The Journal of Infectious Diseases|April 5, 2012
Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidisAnnaliesa S Anderson, Ingrid L Scully, Yekaterina Timofeyeva, et al.
Obstetrics and Gynecology|January 6, 2006
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trialConstance Mao, Laura A Koutsky, Kevin A Ault, et al.
Mayo Clinic Proceedings|May 13, 2005
Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trialGregory A Poland, Robert M Jacobson, Laura A Koutsky, et al.
Journal of the Pediatric Infectious Diseases Society|January 25, 2016
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy AdolescentsTimo Vesikari, Jacek Wysocki, Johannes Beeslaar, et al.
Vaccine|August 31, 2015
Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infectionIngrid L Scully, Yekaterina Timofeyeva, David Keeney, et al.
Vaccine|May 22, 2013
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and olderLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Acta Obstetricia Et Gynecologica Scandinavica|October 19, 2007
Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristicsFinn Egil Skjeldestad, Vinay Mehta, Heather L Sings, et al.
Vaccine|August 7, 2004
A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineKevin A Ault, Anna R Giuliano, Robert P Edwards, et al.
The Pediatric Infectious Disease Journal|October 19, 2013
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Shelly Senders, et al.
Pageof 26